Loading…

Effect of Melatonin on Cognitive Function and Sleep in relation to Breast Cancer Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial

Background. Sleep disturbances and cognitive dysfunction are common in patients with breast cancer. Disturbed sleep leads to poor cognitive performance and exogenous melatonin may improve sleep and attenuate cognitive dysfunction. We hypothesized that melatonin would improve sleep and cognitive func...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Breast Cancer 2014-01, Vol.2014 (2014), p.54-62
Main Authors: Gögenur, Ismail, Bokmand, Susanne, Rasmussen, Lars Simon, Hageman, Ida, Andersen, Lærke Toftegård, Madsen, Michael Tvilling, Hansen, Melissa Voigt, Rosenberg, Jacob
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a627t-7a24944624bf5741242ee1e5a662c014de61b802dfb0855bfe5fbc831128f1583
cites cdi_FETCH-LOGICAL-a627t-7a24944624bf5741242ee1e5a662c014de61b802dfb0855bfe5fbc831128f1583
container_end_page 62
container_issue 2014
container_start_page 54
container_title International Journal of Breast Cancer
container_volume 2014
creator Gögenur, Ismail
Bokmand, Susanne
Rasmussen, Lars Simon
Hageman, Ida
Andersen, Lærke Toftegård
Madsen, Michael Tvilling
Hansen, Melissa Voigt
Rosenberg, Jacob
description Background. Sleep disturbances and cognitive dysfunction are common in patients with breast cancer. Disturbed sleep leads to poor cognitive performance and exogenous melatonin may improve sleep and attenuate cognitive dysfunction. We hypothesized that melatonin would improve sleep and cognitive function after surgery. Methods. This study reports secondary endpoints from a randomized, double-blind, placebo-controlled trial. Women, 30–75 years, were randomized to 6mg oral melatonin/placebo for 3 months. We assessed postoperative cognitive dysfunction (POCD) with a neuropsychological test battery, sleep with a diary, and sleep quality with VAS. Results. 54 patients were randomized to melatonin ( n = 28 ) or placebo ( n = 26 ); 11 withdrew (10 placebo, 1 melatonin, P = 0.002 ). The incidence of POCD was 0% (0/20) [95% CI 0.0%; 16.8%] in the placebo group and 0% (0/26) [95% CI 0.0%; 13.2%] in the melatonin group 2 weeks postoperatively ( P = 1.00 ) and 6.3% (1/16) [95% CI 0.0%; 30.2%] in the placebo group and 0% (0/26) [95% CI 0.0%; 13.2%] in the melatonin group 12 weeks postoperatively ( P = 0.38 ). Sleep efficiency was significantly greater in the melatonin group; mean difference was 4.28% [95% CI 0.57; 7.82] ( P = 0.02 ). The total sleep period was significantly longer in the melatonin group; mean difference was 37.0 min [95% CI 3.6; 69.7] ( P = 0.03 ). Conclusion. Melatonin increased sleep efficiency and total sleep time but did not affect cognitive function. The dropout rate was significantly lower in the melatonin group. This trial is registered with Clinicaltrials.gov NCT01355523.
doi_str_mv 10.1155/2014/416531
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_cd429f2abba14bcdad17b1e9d1c3c675</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A418226744</galeid><airiti_id>P20151207002_201412_201512070002_201512070002_54_62</airiti_id><doaj_id>oai_doaj_org_article_cd429f2abba14bcdad17b1e9d1c3c675</doaj_id><sourcerecordid>A418226744</sourcerecordid><originalsourceid>FETCH-LOGICAL-a627t-7a24944624bf5741242ee1e5a662c014de61b802dfb0855bfe5fbc831128f1583</originalsourceid><addsrcrecordid>eNqNks1u1DAUhSMEolXpij2yhIQQMNTXf0lYILVDC0VFVLSsLce5mXHliYuTFJWH4JlxJkNpu8Ib29efj3x8T5Y9BfoWQMo9RkHsCVCSw4Nsm9GSzjgU5cObdU63st2uu6BpSOBc5Y-zLSY5K3KA7ez3YdOg7UloyBf0pg-ta0loyTwsWte7KyRHQ2t7l0qmrcmZR7wkCYkjPFb7QA4imq4nc9NajORsiAuM1-_IPvmWroSV-4X1G_IhDJXH2YF3bdqdemOxCrN5aPsYvMeanEdn_JPsUWN8h7ubeSf7fnR4Pv80O_n68Xi-fzIziuX9LDdMlEIoJqpG5gKYYIiA0ijFbPqRGhVUBWV1U9FCyqpB2VS24ACsaEAWfCc7nnTrYC70ZXQrE691ME6vCyEutIm9sx61rQUrG2aqyoCobG1qyCvAsgbLrcpl0no_aV0O1Qpri8mS8XdE7560bqkX4UqntlFFx8e83AjE8GPArtcr11n03rQYhk6DAqHKUjGV0Of30IswxDZ9lU6dLpNBzkfBFxO1MMnAEo3vl13ww9iwTu8LKBhTuRAJfD2BNoaui9jcvBqoHvOlx3zpKV-Jfnbb6A37N00JeDUBy9Rk89P9nxomBBtzC-aKU5qAzxNgXExR_Of0NMlIYDSnlK0lYT1tSvTeRgqtGP8D6Zf0EQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1709311338</pqid></control><display><type>article</type><title>Effect of Melatonin on Cognitive Function and Sleep in relation to Breast Cancer Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial</title><source>Wiley-Blackwell Open Access Titles</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Gögenur, Ismail ; Bokmand, Susanne ; Rasmussen, Lars Simon ; Hageman, Ida ; Andersen, Lærke Toftegård ; Madsen, Michael Tvilling ; Hansen, Melissa Voigt ; Rosenberg, Jacob</creator><contributor>Fentiman, Ian S.</contributor><creatorcontrib>Gögenur, Ismail ; Bokmand, Susanne ; Rasmussen, Lars Simon ; Hageman, Ida ; Andersen, Lærke Toftegård ; Madsen, Michael Tvilling ; Hansen, Melissa Voigt ; Rosenberg, Jacob ; Fentiman, Ian S.</creatorcontrib><description>Background. Sleep disturbances and cognitive dysfunction are common in patients with breast cancer. Disturbed sleep leads to poor cognitive performance and exogenous melatonin may improve sleep and attenuate cognitive dysfunction. We hypothesized that melatonin would improve sleep and cognitive function after surgery. Methods. This study reports secondary endpoints from a randomized, double-blind, placebo-controlled trial. Women, 30–75 years, were randomized to 6mg oral melatonin/placebo for 3 months. We assessed postoperative cognitive dysfunction (POCD) with a neuropsychological test battery, sleep with a diary, and sleep quality with VAS. Results. 54 patients were randomized to melatonin ( n = 28 ) or placebo ( n = 26 ); 11 withdrew (10 placebo, 1 melatonin, P = 0.002 ). The incidence of POCD was 0% (0/20) [95% CI 0.0%; 16.8%] in the placebo group and 0% (0/26) [95% CI 0.0%; 13.2%] in the melatonin group 2 weeks postoperatively ( P = 1.00 ) and 6.3% (1/16) [95% CI 0.0%; 30.2%] in the placebo group and 0% (0/26) [95% CI 0.0%; 13.2%] in the melatonin group 12 weeks postoperatively ( P = 0.38 ). Sleep efficiency was significantly greater in the melatonin group; mean difference was 4.28% [95% CI 0.57; 7.82] ( P = 0.02 ). The total sleep period was significantly longer in the melatonin group; mean difference was 37.0 min [95% CI 3.6; 69.7] ( P = 0.03 ). Conclusion. Melatonin increased sleep efficiency and total sleep time but did not affect cognitive function. The dropout rate was significantly lower in the melatonin group. This trial is registered with Clinicaltrials.gov NCT01355523.</description><identifier>ISSN: 2090-3170</identifier><identifier>ISSN: 2090-3189</identifier><identifier>EISSN: 2090-3189</identifier><identifier>DOI: 10.1155/2014/416531</identifier><identifier>PMID: 25328711</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Limiteds</publisher><subject>Breast ; Breast cancer ; Cancer ; Care and treatment ; Clinical Study ; Evaluation ; Health aspects ; Melatonin ; Quality of life ; Risk factors ; Sleep disorders ; Surgery</subject><ispartof>International Journal of Breast Cancer, 2014-01, Vol.2014 (2014), p.54-62</ispartof><rights>Copyright © 2014 Melissa Voigt Hansen et al.</rights><rights>COPYRIGHT 2014 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2014 Melissa Voigt Hansen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2014 Melissa Voigt Hansen et al. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a627t-7a24944624bf5741242ee1e5a662c014de61b802dfb0855bfe5fbc831128f1583</citedby><cites>FETCH-LOGICAL-a627t-7a24944624bf5741242ee1e5a662c014de61b802dfb0855bfe5fbc831128f1583</cites><orcidid>0000-0001-7116-2216 ; 0000-0002-0063-1086</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1709311338/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1709311338?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25328711$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Fentiman, Ian S.</contributor><creatorcontrib>Gögenur, Ismail</creatorcontrib><creatorcontrib>Bokmand, Susanne</creatorcontrib><creatorcontrib>Rasmussen, Lars Simon</creatorcontrib><creatorcontrib>Hageman, Ida</creatorcontrib><creatorcontrib>Andersen, Lærke Toftegård</creatorcontrib><creatorcontrib>Madsen, Michael Tvilling</creatorcontrib><creatorcontrib>Hansen, Melissa Voigt</creatorcontrib><creatorcontrib>Rosenberg, Jacob</creatorcontrib><title>Effect of Melatonin on Cognitive Function and Sleep in relation to Breast Cancer Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial</title><title>International Journal of Breast Cancer</title><addtitle>Int J Breast Cancer</addtitle><description>Background. Sleep disturbances and cognitive dysfunction are common in patients with breast cancer. Disturbed sleep leads to poor cognitive performance and exogenous melatonin may improve sleep and attenuate cognitive dysfunction. We hypothesized that melatonin would improve sleep and cognitive function after surgery. Methods. This study reports secondary endpoints from a randomized, double-blind, placebo-controlled trial. Women, 30–75 years, were randomized to 6mg oral melatonin/placebo for 3 months. We assessed postoperative cognitive dysfunction (POCD) with a neuropsychological test battery, sleep with a diary, and sleep quality with VAS. Results. 54 patients were randomized to melatonin ( n = 28 ) or placebo ( n = 26 ); 11 withdrew (10 placebo, 1 melatonin, P = 0.002 ). The incidence of POCD was 0% (0/20) [95% CI 0.0%; 16.8%] in the placebo group and 0% (0/26) [95% CI 0.0%; 13.2%] in the melatonin group 2 weeks postoperatively ( P = 1.00 ) and 6.3% (1/16) [95% CI 0.0%; 30.2%] in the placebo group and 0% (0/26) [95% CI 0.0%; 13.2%] in the melatonin group 12 weeks postoperatively ( P = 0.38 ). Sleep efficiency was significantly greater in the melatonin group; mean difference was 4.28% [95% CI 0.57; 7.82] ( P = 0.02 ). The total sleep period was significantly longer in the melatonin group; mean difference was 37.0 min [95% CI 3.6; 69.7] ( P = 0.03 ). Conclusion. Melatonin increased sleep efficiency and total sleep time but did not affect cognitive function. The dropout rate was significantly lower in the melatonin group. This trial is registered with Clinicaltrials.gov NCT01355523.</description><subject>Breast</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Clinical Study</subject><subject>Evaluation</subject><subject>Health aspects</subject><subject>Melatonin</subject><subject>Quality of life</subject><subject>Risk factors</subject><subject>Sleep disorders</subject><subject>Surgery</subject><issn>2090-3170</issn><issn>2090-3189</issn><issn>2090-3189</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNks1u1DAUhSMEolXpij2yhIQQMNTXf0lYILVDC0VFVLSsLce5mXHliYuTFJWH4JlxJkNpu8Ib29efj3x8T5Y9BfoWQMo9RkHsCVCSw4Nsm9GSzjgU5cObdU63st2uu6BpSOBc5Y-zLSY5K3KA7ez3YdOg7UloyBf0pg-ta0loyTwsWte7KyRHQ2t7l0qmrcmZR7wkCYkjPFb7QA4imq4nc9NajORsiAuM1-_IPvmWroSV-4X1G_IhDJXH2YF3bdqdemOxCrN5aPsYvMeanEdn_JPsUWN8h7ubeSf7fnR4Pv80O_n68Xi-fzIziuX9LDdMlEIoJqpG5gKYYIiA0ijFbPqRGhVUBWV1U9FCyqpB2VS24ACsaEAWfCc7nnTrYC70ZXQrE691ME6vCyEutIm9sx61rQUrG2aqyoCobG1qyCvAsgbLrcpl0no_aV0O1Qpri8mS8XdE7560bqkX4UqntlFFx8e83AjE8GPArtcr11n03rQYhk6DAqHKUjGV0Of30IswxDZ9lU6dLpNBzkfBFxO1MMnAEo3vl13ww9iwTu8LKBhTuRAJfD2BNoaui9jcvBqoHvOlx3zpKV-Jfnbb6A37N00JeDUBy9Rk89P9nxomBBtzC-aKU5qAzxNgXExR_Of0NMlIYDSnlK0lYT1tSvTeRgqtGP8D6Zf0EQ</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Gögenur, Ismail</creator><creator>Bokmand, Susanne</creator><creator>Rasmussen, Lars Simon</creator><creator>Hageman, Ida</creator><creator>Andersen, Lærke Toftegård</creator><creator>Madsen, Michael Tvilling</creator><creator>Hansen, Melissa Voigt</creator><creator>Rosenberg, Jacob</creator><general>Hindawi Limiteds</general><general>Hindawi Publishing Corporation</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><general>Wiley</general><scope>188</scope><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PADUT</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7116-2216</orcidid><orcidid>https://orcid.org/0000-0002-0063-1086</orcidid></search><sort><creationdate>20140101</creationdate><title>Effect of Melatonin on Cognitive Function and Sleep in relation to Breast Cancer Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial</title><author>Gögenur, Ismail ; Bokmand, Susanne ; Rasmussen, Lars Simon ; Hageman, Ida ; Andersen, Lærke Toftegård ; Madsen, Michael Tvilling ; Hansen, Melissa Voigt ; Rosenberg, Jacob</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a627t-7a24944624bf5741242ee1e5a662c014de61b802dfb0855bfe5fbc831128f1583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Breast</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Clinical Study</topic><topic>Evaluation</topic><topic>Health aspects</topic><topic>Melatonin</topic><topic>Quality of life</topic><topic>Risk factors</topic><topic>Sleep disorders</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gögenur, Ismail</creatorcontrib><creatorcontrib>Bokmand, Susanne</creatorcontrib><creatorcontrib>Rasmussen, Lars Simon</creatorcontrib><creatorcontrib>Hageman, Ida</creatorcontrib><creatorcontrib>Andersen, Lærke Toftegård</creatorcontrib><creatorcontrib>Madsen, Michael Tvilling</creatorcontrib><creatorcontrib>Hansen, Melissa Voigt</creatorcontrib><creatorcontrib>Rosenberg, Jacob</creatorcontrib><collection>Airiti Library</collection><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central (subscription)</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Research Library China</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied &amp; Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International Journal of Breast Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gögenur, Ismail</au><au>Bokmand, Susanne</au><au>Rasmussen, Lars Simon</au><au>Hageman, Ida</au><au>Andersen, Lærke Toftegård</au><au>Madsen, Michael Tvilling</au><au>Hansen, Melissa Voigt</au><au>Rosenberg, Jacob</au><addau>Fentiman, Ian S.</addau><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Melatonin on Cognitive Function and Sleep in relation to Breast Cancer Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial</atitle><jtitle>International Journal of Breast Cancer</jtitle><addtitle>Int J Breast Cancer</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>2014</volume><issue>2014</issue><spage>54</spage><epage>62</epage><pages>54-62</pages><issn>2090-3170</issn><issn>2090-3189</issn><eissn>2090-3189</eissn><abstract>Background. Sleep disturbances and cognitive dysfunction are common in patients with breast cancer. Disturbed sleep leads to poor cognitive performance and exogenous melatonin may improve sleep and attenuate cognitive dysfunction. We hypothesized that melatonin would improve sleep and cognitive function after surgery. Methods. This study reports secondary endpoints from a randomized, double-blind, placebo-controlled trial. Women, 30–75 years, were randomized to 6mg oral melatonin/placebo for 3 months. We assessed postoperative cognitive dysfunction (POCD) with a neuropsychological test battery, sleep with a diary, and sleep quality with VAS. Results. 54 patients were randomized to melatonin ( n = 28 ) or placebo ( n = 26 ); 11 withdrew (10 placebo, 1 melatonin, P = 0.002 ). The incidence of POCD was 0% (0/20) [95% CI 0.0%; 16.8%] in the placebo group and 0% (0/26) [95% CI 0.0%; 13.2%] in the melatonin group 2 weeks postoperatively ( P = 1.00 ) and 6.3% (1/16) [95% CI 0.0%; 30.2%] in the placebo group and 0% (0/26) [95% CI 0.0%; 13.2%] in the melatonin group 12 weeks postoperatively ( P = 0.38 ). Sleep efficiency was significantly greater in the melatonin group; mean difference was 4.28% [95% CI 0.57; 7.82] ( P = 0.02 ). The total sleep period was significantly longer in the melatonin group; mean difference was 37.0 min [95% CI 3.6; 69.7] ( P = 0.03 ). Conclusion. Melatonin increased sleep efficiency and total sleep time but did not affect cognitive function. The dropout rate was significantly lower in the melatonin group. This trial is registered with Clinicaltrials.gov NCT01355523.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Limiteds</pub><pmid>25328711</pmid><doi>10.1155/2014/416531</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-7116-2216</orcidid><orcidid>https://orcid.org/0000-0002-0063-1086</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2090-3170
ispartof International Journal of Breast Cancer, 2014-01, Vol.2014 (2014), p.54-62
issn 2090-3170
2090-3189
2090-3189
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_cd429f2abba14bcdad17b1e9d1c3c675
source Wiley-Blackwell Open Access Titles; Publicly Available Content Database; PubMed Central
subjects Breast
Breast cancer
Cancer
Care and treatment
Clinical Study
Evaluation
Health aspects
Melatonin
Quality of life
Risk factors
Sleep disorders
Surgery
title Effect of Melatonin on Cognitive Function and Sleep in relation to Breast Cancer Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-03-06T14%3A56%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Melatonin%20on%20Cognitive%20Function%20and%20Sleep%20in%20relation%20to%20Breast%20Cancer%20Surgery:%20A%20Randomized,%20Double-Blind,%20Placebo-Controlled%20Trial&rft.jtitle=International%20Journal%20of%20Breast%20Cancer&rft.au=G%C3%B6genur,%20Ismail&rft.date=2014-01-01&rft.volume=2014&rft.issue=2014&rft.spage=54&rft.epage=62&rft.pages=54-62&rft.issn=2090-3170&rft.eissn=2090-3189&rft_id=info:doi/10.1155/2014/416531&rft_dat=%3Cgale_doaj_%3EA418226744%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a627t-7a24944624bf5741242ee1e5a662c014de61b802dfb0855bfe5fbc831128f1583%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1709311338&rft_id=info:pmid/25328711&rft_galeid=A418226744&rft_airiti_id=P20151207002_201412_201512070002_201512070002_54_62&rfr_iscdi=true